commercial suppliers and were used without further purification. Reactions
were monitored by LCMS (Agilent 1100 Series) equipped with an ESI-MS
detector (Waters Micromass ZQ 2000) or by TLC-MS (API, Advion Expression).
The phosphonamidate series were purified with preparative RP-HPLC
(VWR LaPrep P110) with single wavelength detection (254 nm), using
an ACE5 C8 column (5 μm, 100 Å, ϕ 21.2 mm L 250 mm)
and gradients of CH3CN/H2O as the mobile phase
at a 10 mL/min flow rate. NMR spectra of the synthetic intermediates
were recorded on a Varian Unity 400 MHz, Bruker Avance Neo 500 MHz,
or a Bruker Avance Neo 600 MHz spectrometer. The Bruker instruments
were equipped with TXO and TCI cryogenic probes. The chemical shifts
are reported using the residual solvent signal as an indirect reference
to TMS. Chemical shift titrations and 3D NOESY were acquired on the
Bruker Avance Neo 600 MHz spectrometer, whereas spectra for assignment
were obtained on the Bruker Avance HD 800 MHz spectrometer equipped
with a 3 mm TCI cryogenic probe. Purity analysis of the final phosphonamidate
inhibitors was performed using 1H NMR, with the original
spectra being shown in the
at Zenodo (